retatrutide clinical trials weight loss Seeking Differentiation Through a Triple Mechanism" Eli Lilly's Again Proves Efficacy in Trials, Raising Question of Whether It Can Overcome Side-Effect Limits and Reshape the Market Triple hormone receptor agonist retatrutide

Importantly, the reduction in LBM was modest relative to the overall BW loss, suggesting that GLP-1 RAs favor selective adipose tissue reduction over loss of lean tissue

Tirzepatide is typically administered as a subcutaneous injection once a week

(Source: Healthline, 2026) The BALANCE Model Has Been Delayed Indefinitely CMS originally announced two programs: the GLP-1 Bridge Program and the BALANCE model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), a five-year CMS Innovation Center model that would have let Part D plans opt in to covering weight loss GLP-1s starting January 2027

As of March 2025, 11 states cover GLP-1s for weight loss under their state employee health plan, nine states provide coverage under their state Medicaid program, and five states provide coverage under both programs

Never obtain GLP-1 or GIP medicines without a prescription or from unregulated sources, as this poses serious health risks

Monthly waist circumference measurements capture body composition changes that scales miss